Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
NewcelX ( (NCEL) ) has issued an announcement.
On March 9, 2026, NewcelX announced a strategic research collaboration with Eledon Pharmaceuticals to combine its NCEL-101 stem-cell-derived islet program with Eledon’s investigational anti-CD40L antibody tegoprubart for Type 1 diabetes. The partners plan to integrate targeted immune modulation with NewcelX’s off-the-shelf islet replacement to support durable, immune-protected graft survival that could resemble outcomes seen with donor human islets.
NewcelX expects Eledon’s experience from more than 100 transplant procedures to provide clinically informed insight and data relevant to cell replacement therapies, potentially clarifying the regulatory pathway and streamlining development of NCEL-101. Executives described the alliance as a key strategic milestone intended to accelerate timelines, enhance development visibility, and support disciplined execution toward pivotal clinical milestones and long-term value for stakeholders.
More about NewcelX
NewcelX Ltd. is a Switzerland-based, clinical-stage biopharmaceutical company focused on developing stem-cell-derived therapies for Type 1 diabetes. Built on a human pluripotent stem cell platform, its lead program NCEL-101 aims to restore functional insulin production via scalable, off-the-shelf islet cell replacement that integrates cell therapy, immune protection, and translational science to address unmet medical need.
Average Trading Volume: 105,990
Technical Sentiment Signal: Sell
Current Market Cap: $12.63M
Learn more about NCEL stock on TipRanks’ Stock Analysis page.